Last reviewed · How we verify
Tapentadol ER 250-mg TRF tablet
Tapentadol ER 250-mg TRF tablet is a Small molecule drug developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. It is currently in Phase 1 development.
At a glance
| Generic name | Tapentadol ER 250-mg TRF tablet |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tapentadol ER 250-mg TRF tablet CI brief — competitive landscape report
- Tapentadol ER 250-mg TRF tablet updates RSS · CI watch RSS
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. portfolio CI
Frequently asked questions about Tapentadol ER 250-mg TRF tablet
What is Tapentadol ER 250-mg TRF tablet?
Tapentadol ER 250-mg TRF tablet is a Small molecule drug developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
Who makes Tapentadol ER 250-mg TRF tablet?
Tapentadol ER 250-mg TRF tablet is developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (see full Johnson & Johnson Pharmaceutical Research & Development, L.L.C. pipeline at /company/johnson-johnson-pharmaceutical-research-development-l-l-c).
What development phase is Tapentadol ER 250-mg TRF tablet in?
Tapentadol ER 250-mg TRF tablet is in Phase 1.